NO DECISIONPending Review93% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on overall Survival?
Found
Summary
No OS efficacy readout is available. ClinicalTrials.gov shows NCT06520345 is recruiting with no results posted and estimated primary completion in Dec 2027. Public updates report only Part 1 safety/dosimetry and Part 2 initiation, not overall survival efficacy.
Sources
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06520345 | 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC
Registry lists the trial as Recruiting, with No Results Posted; primary completion is estimated Dec 2027 and the primary objective is rPFS comparison.
Sponsortelixpharma.com
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion
Telix says Part 2 randomized expansion has just begun and that preliminary Part 1 results would be disclosed after FDA engagement; no OS result reported.
Web Searchurologytimes.com
Lutetium-177 rosopatamab tetraxetan meets primary safety objectives in phase 3 trial for mCRPC
Article describes Part 1 as meeting primary safety/dosimetry objectives and notes Part 2 randomized expansion will enroll about 490 patients; not an OS efficacy readout.